Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Chongqing Claruvis Pharmaceutical Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area, with 1 pending office action currently in its portfolio. This single action indicates a focused prosecution effort for its pharmaceutical technologies. The examination process is concentrated, involving 1 distinct examiner and 1 distinct art unit, which suggests a focused technical scope for the company's current patent filings.
The involvement of 1 distinct art unit means that the 1 pending office action is being reviewed by a group specialized in the relevant pharmaceutical systems. For the practitioner, the 1 distinct examiner is the only official reviewing the company's claims, making their individual interpretation of the law and technology the primary factor. This 1 distinct examiner provides a consistent point of contact for the prosecution of the 1 pending office action.
EIX, EMILY FAY is the busiest examiner for the company, currently handling 1 busiest examiner pending office action. As this 1 action is the only pending matter in the portfolio, EIX, EMILY FAY is the central figure in the company's current patent office interactions. Resolving the 1 busiest examiner pending office action with EIX, EMILY FAY is essential for securing the company's intellectual property in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EIX, EMILY FAY | 1 | 45.5% | +78.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547979 | MODIFIED NEUROTOXIN SINGLE-CHAIN POLYPEPTIDE AND USE THEREOF | EIX, EMILY FAY | 22d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547979 | MODIFIED NEUROTOXIN SINGLE-CHAIN POLYPEPTIDE AND USE THEREOF | EIX, EMILY FAY | 1653 | §103Other | Final Rejection | 22d | Pending | Aug 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial